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highly DC2 selective. Selective clones were DNA sequenced re-
vealing the random peptide insert. A 1-way MLR was performed
with varying dilution of each ampliﬁed DC2 speciﬁc phage to
demonstrate the cellular affects on allogeneic T-cell proliferation.
Results: Plaque assays from the monocyte adsorbed or non-ad-
sorbed linear random peptide library after the three rounds of
panning revealed two consensus sequences in 76 of the 78 (97%)
isolated clones that were DC2 selective and one sequence found
twice (3%) that was non-DC2 selective. The employed circular
random peptide library revealed no DC2 selective sequences from
15 isolated in clones from the monocyte adsorbed and non-ad-
sorbed plaque assays. Preliminary MLR data shows a 35 % reduc-
tion in allogeneic T-cell proliferation with the DC2 speciﬁc phage
compared to control phage. Conclusions: Data shows that phage
display technology can result in isolating highly speciﬁc DC2
peptides from a library of 10,000 different phage clones. Prelimi-
nary data suggests that binding DC2 speciﬁc peptides may inhibit
the function of these immunoregulatory cells, leading to enhanced
anti-tumor affect of the transplanted donor graft product by shift-
ing it towards an activated Th1 immune response.
GVH/GVL
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TREATMENT WITH GRANULOCYTE COLONY-STIMULATING FACTOR
AFTER ALLOGENEIC BONE MARROW TRANSPLANTATION FOR ACUTE
LEUKEMIA INCREASES THE RISK OF GRAFT-VERSUS-HOST DISEASE
AND DEATH
Ringde´n, O.1, Labopin, M.2, Gorin, N.C.2, Le Blanc, K.1, Rocha, V.3,
Gluckman, E.3, Reiffers, J.4, Arcese, W.5, Vossen, J.M.6, Jouet, J.-P.7,
Cordonnier, C.8, Frassoni, F.9 1. Centre for Allogeneic Stem Cell Trans-
plantation and Division of Clinical Immunology, Huddinge Univ. Hos-
pital, Stockholm, Sweden; 2. Hopital Saint-Antoine and EBMT Data
Center, Institut des Cordeliers, Paris, France; 3. Hopital Saint-Louis,
Paris, France; 4. GRP Hopital de Haut-Leve`que, Pessac, France; 5.
University La Sapienza, Rome, Italy; 6. BMT Centre, Leiden University
Hospital, Leiden, Netherlands; 7. Service des Maladies du Sang, Hospital
Claude Huriez, Lille, France; 8. Hospital Henri Mondor, Creteil,
France; 9. Ospedale San Martino, Genova, Italy
Purpose: Granulocyte colony-stimulating factor (G-CSF) is
given after bone marrow transplantation (BMT) to shorten the
neutropenic phase. Its effects have not been evaluated in a large
patient population. Patients and Methods: We studied 1789 pa-
tients with acute leukaemia receiving BMT and 434 patients re-
ceiving peripheral blood stem cells (PBSC) from HLA-identical
siblings from 1992 to 2002 and reported the ﬁndings to the Eu-
ropean Group for Blood and Marrow Transplantation (EBMT).
Among the BMT and PBSC patients, 501 (28%) and 175 (40%),
respectively, were treated with G-CSF during the ﬁrst 14 days after
the transplant. The outcome variables were entered in a Cox
proportional hazard model. Results: BMT and PBSC patients
treated with G-CSF had a faster engraftment of absolute neutro-
phils 0.5  109/l (p  0.01), but platelet engraftment (50 
109/l) was slower (p  0.001). In the BMT patients, acute graft-
versus-host disease (GVHD) grades II-IV was 50  5% (95%
conﬁdence interval) in the G-CSF group vs. 39  3% in the
controls (relative risk (RR) 1.33, p  0.007, in the multivariate
analysis). The incidence of chronic GVHD was also increased (RR
0.29, p  0.03).
G-CSF was associated with an increase in transplant-related
mortality (TRM) (RR 1.73, p  0.00016), had no effect on relapse,
but reduced the survival (RR 1.7, p  0.0001) and leukaemia-free
survival rates (LFS) (RR 1.55, p  0.0003). No such effects of
G-CSF were seen in patients receiving PBSC. Conclusion: After
BMT, platelet engraftment was delayed, and GVHD and TRM
were increased. Survival and LFS were reduced. This suggests that
G-CSF should not be given shortly after BMT.
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SUBEROYLANILIDE HYDROXAMIC ACID REDUCES ACUTE GRAFT-VER-
SUS-HOST DISEASE AND PRESERVES GRAFT-VERSUS-LEUKEMIA EF-
FECT BY INHIBITING HISTONE DEACETYLATION
Reddy, P.1, Maeda, Y.1, Hotary, K.1, Dinarello, C.A.2, Ferrara, J.L.1 1.
University of Michigan Comprehensive Cancer Center, Ann Arbor, MI;
2. University of Colorado Medical Center, Denver, CO
Pro-inﬂammatory cytokines and the loss of gastrointestinal tract
integrity contribute to acute graft-versus-host disease (GVHD)
whereas the donor cytotoxic responses are critical for graft-versus-
leukemia (GVL) preservation. Suberoylanilide hydroxamic acid
(SAHA) is an anti-tumor agent that inhibits the activity of histone
deacetylases (HDAC) and reduces the production of proinﬂamma-
tory cytokines. Using a well characterized allogeneic murine BMT
model B6 (H-2b) 3 B6D2F1 (H-2b/d) we studied the effects of
HDAC inhibition by SAHA on acute GVHD. Recipients were
transplanted with 2x10 6 donor T and 5x106 BM cells after13 GY
TBI. Intra-peritoneal injections of 35 mg/kg/day of SAHA from
days 3 to day 7 increased histone H3 acetylation in splenocytes
harvested 7 days after BMT, conﬁrming the inhibition of HDAC
enzymes. SAHA treatment signiﬁcantly reduced the serum levels of
pro-inﬂammatory cytokines such as TNF-a, IL-1	 and IFN-

(P  0.04) in the allogeneic recipients on day 7 after BMT.
Intracytoplasmic staining by ﬂow cytometry and RPA analysis of
the host splenocytes on day 7 conﬁrmed the decrease in the
cytokine protein and mRNA. SAHA signiﬁcantly improved the
survival (P 0.002) and reduced intestinal damage from GVHD of
the allogeneic recipients . However SAHA did not suppress the
donor T cell expansion in vivo and the proliferative and cytotoxic
responses to host antigens in vitro measured 7 and 14 days after
BMT. To test the effect of SAHA on GVL effects, recipients were
injected with lethal doses of P815 (H-2d) tumor cells at the time of
BMT. SAHA treatment resulted in signiﬁcantly improved leuke-
mia-free survival after allogeneic BMT (P  0.05) whereas all the
syngeneic BMT recipients of SAHA died of tumor ruling out
direct anti-tumor effects of SAHA. Furthermore SAHA increased
H3 acetylation in the splenocytes from both the syngeneic and
allogeneic leukemic recipients on day 7, conﬁrming that inhibi-
tion of HDAC enzymes alone is not sufﬁcient for leukemia free
survival in this system. We also tested the effect of SAHA in a
second allogeneic BMT model (BALB/c 3 B6), where it also
signiﬁcantly improved survival (P  0.001) and preserved GVL
effects when recipient mice were injected with lethal doses of EL-4
(H-2b) tumor (P  0.04). We conclude that HDAC inhibition
regulates acute GVHD in these models and suggest that this class
of pharmacologic agents may provide a novel strategy to reduce
GVHD while maintaining the beneﬁcial GVL effects.
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ABROGATION OF THE INTERACTIONS BETWEEN CXCR3 AND ITS LI-
GANDS MIG AND IP-10 REDUCES THE SEVERITY OF IDIOPATHIC PNEU-
MONIA SYNDROME AFTER ALLOGENEIC STEM CELL TRANSPLANTA-
TION
Hildebrandt, G.C.1, Corrion, L.C.1, Olkiewicz, K.M.1, Liu, C.2, Cooke,
K.R.1 1. Dept. of Pediatrics; BMT Program, University of Michigan,
Ann Arbor, MI; 2. Dept. of Pathology; University of Florida School of
Medicine, Gainesville, FL
Chemokines are important mediators in the development of
Idiopathic Pneumonia Syndrome (IPS), a major cause of mortality
after allogeneic (allo) stem cell transplantation (SCT). We hypoth-
esized, that recruitment of donor T cells to the lung is dependent,
at least in part, upon interactions between the chemokines MIG
and IP-10 and their receptor CXCR3. CXCR3 is expressed on
activated T cells; MIG and IP-10 can be induced in various cell
types by IFN
 alone or in combination with TNFa or IL-1ß. We
tested this hypothesis using an established murine SCT model
wherein lethally irradiated bm1 mice receive SCT from either
syngeneic (bm1) or allogeneic (B6Ly5.2) donors. MIG and IP-10
BAL levels were signiﬁcantly elevated in allo recipients compared
to syn controls at weeks 1 (MIG: 162.8  37.6 vs 0; IP-10: 41.1 
4.2 vs 0 pg/ml) and 4 (MIG: 153.5  41.7 vs 21.6  9.0; IP-10:
202.0  61.1 vs 3.8  0.9 pg/ml) and correlated with the inﬁltra-
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tion of donor T cells into the lung. To examine the effect of these
chemokines on T cell recruitment, we treated allogeneic recipients
with polyclonal antibodies (Abs) against MIG and IP-10 or control
from day 0 until day 28. Lung pathology at day 28 was signiﬁcantly
decreased in the Ab-treated animals and was associated with sig-
niﬁcantly decreased numbers of total cells, CD8T cells and
TNFa levels in the BAL ﬂuid (table 1). MIG/IP-10 neutralization
also resulted in reduced damage to the GI tract by week 1 and 4
(table 1), whereas liver pathology was unaffected. Clinical GVHD
scores were also lower in Ab-treated animals at weeks 5 and 6 after
SCT and correlated with a reduction in mortality during this time.
In a ﬁnal set of experiments, we used CXCR3-/- mice as allo SCT
donors and found that mice receiving CXCR3-/- cells had de-
creased lung injury compared to allo wild-type controls at week 4
as measured by BAL cellularity (1.2  0.1 vs. 2.5  0.4 mio),
CD8T cells (0.06  0.01 vs. 0.17  0.03 mio) and TNFa levels
(9.0  1.8 vs. 33.4  8.0 pg/ml). In conclusion, our data demon-
strate, that interactions between the chemokines MIG and IP-10
and their receptor CXCR3 are important for donor T cell recruit-
ment into the lung and the development of IPS. Approaches
focusing on the abrogation of these interactions may prove suc-
cessful in preventing or treating this serious complication after
allogeneic SCT.
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DONOR LEUKOCYTE-PRODUCTION OF RANTES SIGNIFICANTLY CON-
TRIBUTES TO THE DEVELOPMENT OF IDIOPATHIC PNEUMONIA SYN-
DROME AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
Hildebrandt, G.C.1, Olkiewicz, K.M.1, Corrion, L.C.1, Liu, C.2, Cooke,
K.R.1 1. Dept. of Pediatrics; BMT Program, University of Michigan,
Ann Arbor, MI; 2. Dept. of Pathology; University of Florida School of
Medicine, Gainesville, FL
Idiopathic pneumonia syndrome (IPS) is a major cause of mor-
tality after allogeneic (allo) stem cell transplantation (SCT). IPS
pathophysiology includes the secretion of inﬂammatory cyto- and
chemokines along with the recruitment of donor T cells and
monocytes/macrophages. We hypothesized that leukocyte recruit-
ment during IPS is dependent, at least in part, upon interactions
between RANTES and its primary receptor CCR5: RANTES is
produced predominantly by CD8 T cells, epithelium, and ﬁbro-
blasts and promotes CCR5 T cell and macrophage inﬁltration to
inﬂammatory sites. Using an established mouse SCT model, le-
thally irradiated B6DF1 mice received SCT from syngeneic
(B6D2F1) or allogeneic (B6) donors. Pulmonary CCR5 mRNA
expression was signiﬁcantly increased from week 1 to week 6 in allo
SCT recipients compared to syngeneic controls and correlated
with donor effector cell recruitment to the lung and increasing
histopathology scores over time. Pulmonary RANTES mRNA
expression was signiﬁcantly increased from week 1 to 6 after allo
SCT and correlated with increases in BAL ﬂuid protein levels at
weeks 2 (277.7  21.2 vs 18.2  18.2 pg/ml) and 6 (103.3  40.1
vs 0.8  0.8 pg/ml). Furthermore, percentages of RANTES se-
creting CD4 and CD8 T cells were signiﬁcantly increased in
lungs of allo SCT recipients by week 2 after transplant (CD4:
14.8  5.5 vs 0.7  0.2; CD8: 17.2  5.9 vs 0.6  0.2). This
suggested that RANTES production from donor effector cells
contributes to the evolution of IPS. We next used wild type (wt) or
RANTES-/- mice as allo SCT donors. Lung injury after RAN-
TES-/- SCT was signiﬁcantly reduced by week 6 compared to wt
controls and was associated with decreases in total BAL cellularity
and in numbers of CD8 and CD4 T cells (Table 1). Although
survival (wt: 54% vs RANTES-/-: 66%) and clinical GVHD score
(wt: 4.8  0.4 vs RANTES-/-: 4.1  0.4) were not different
between groups, injury to GI tract and liver was decreased after
RANTES-/- SCT (Table 1). We next completed mixing experi-
ments wherein wt or RANTES-/- bone marrow was supplemented
with either wt or RANTES-/- T cells and found that RANTES
from both cellular sources contributes to IPS. Collectively, these
data demonstrate that RANTES production by donor leukocytes is
important to the development of lung, intestinal and hepatic dam-
age after allo SCT and suggest that strategies which disrupt
RANTES:CCR5 interactions may be helpful in treating or pre-
venting IPS and target organ GVHD.
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ANTIBODY RESPONSE TO H-Y MINOR HISTOCOMPATIBILITY ANTI-
GENS CORRELATES WITH CHRONIC GRAFT VERSUS HOST DISEASE AND
DISEASE REMISSION
Miklos, D.B., Kim, H.T., Miller, K.H., Guo, L., Zorn, E., Hochberg,
E.P., Lee, S.J., Soiffer, R.J., Antin, J.H., Ritz, J. Dana-Farber Cancer
Institute, Boston, MA
H-Y antigens are important targets of graft versus host disease
(GVHD) and graft versus leukemia in male patients who receive
hematopoietic stem cell transplants from female donors (F 3 M
HSCT). In previous studies, we demonstrated that male patients
who receive stem cells from female donors (F 3 M HSCT)
frequently develop antibody responses to H-Y antigen DBY. To
determine whether other Y-chromosome encoded proteins elicit
B-cell immune responses in F 3 M HSCT, we developed ELISA
for 5 H- Y antigens: DBY, UTY, ZFY, RPS4Y and EIF1AY and
their respective X-homologues. Serum samples from 125 HSCT
patients and 136 normal donors were tested (Table below). Over-
all, 51% of male patients with female donors developed antibody to
at least 1 H-Y antigen compared to 18% with antibody to any H-X
homolog (p  0.001). All H-X responders were also H-Y respond-
ers, and the magnitude of each H-Y response was greater than the
corresponding H-X response. Normal males and M 3 M HSCT
patients rarely had antibody detected for any H-Y antigen, how-
ever 41% of females had antibody detected for at least one H-Y
antigen. F3MHSCT serial samples revealed: 1) antibody to H-Y
antigens were absent pre-HSCT, 2) DBY antibody developed 4-8
months post-HSCT either concurrently or before UTY, ZFY, and
RPS4Y antibodies, and 3) each H-Y antibody response persisted
for at least two years post-HSCT. In order to explore the clinical
signiﬁcance of B-cell response to H-Y antigens, we measured 66
well-characterized F3MHSCT patients six months to two years
post-HSCT with our novel ﬁve H-Y antigens ELISA panel and
correlated these results with clinical outcome. The overall inci-
dence of limited or extensive cGVHD in this cohort was 53%. The
presence of an antibody response to 1 or more H-Y antigens was
highly signiﬁcantly correlated with the development of cGVHD
(p  0.001), and persistent disease remission (p  0.001). Logistic
regression models examining donor age, patient age, unrelated
donor, HLA-mismatched donor, stem cell source, disease, T cell
depletion, or nonmyeloablative conditioning failed to establish
association of these risk factors with either cGVHD or H-Y sero-
Table.
Lung
Path.
Total
BAL
Cells
(mio.)
BAL CD8
Cells (mio.)
BAL
TNF
(pg/mL)
Gut
Path.
Week 1
Gut Path.
Week 4
Synctrl 1.40.4 0.60.04 0.040.003 6.90.1 8.00.6 13.01.0
Alloctrl 5.30.4 1.60.38 0.190.047 20.83.2 23.21.6 19.52.3
Alloanti-
MIG/IP-
10 3.50.4* 0.40.04* 0.020.002* 7.83.0* 13.81.6* 13.21.6 ()
*P  .05; () P  .06.
Table.
Group
Lung
Path.
BAL
Cellularity
(mio.)
BAL
CD8
(mio.)
BAL
CD4
(mio.)
GI Tract
Path.
Liver
Path.
Syngeneic 0.2  0.1 0.7  0.3 0.01  0.01 0.1  0.1 4.6  0.8 1.6  0.3
Allo wt 5.3  0.6 2.5  0.2 0.7  0.1 0.5  0.1 14.0  0.8 14.1  1.0
Allo
RANTES/
2.5  0.5* 0.8  0.2* 0.3  0.1* 0.3  0.1 10.6  1.4* 8.6  0.7*
*P  .05.
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